Alex Rampotas, MBBS, MRCP, University College London, London, UK, comments on the real-world efficacy and safety of momelotinib in patients with myelofibrosis (MF). In patients who received the drug for six months, an encouraging anemia response was observed, and the toxicity profile of the agent was favorable, with the most common adverse event being Grade 1 or 2 peripheral neuropathy that did not significantly impact treatment continuation. Dr Rampotas emphasizes that momelotinib is a valuable therapeutic option for patients with MF. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Ещё видео!